Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Inclusion Criteria:

Patients with histopathologically proven adenocarcinoma of the prostate
Patients must have progressive disease
Patients must have had prior treatment with bilateral orchiectomy or androgen deprivation therapy with an LHRH-blocker with evidence of treatment failure

Exclusion Criteria:

Patients treated with other secondary hormonal therapies
Patients with prior chemotherapy given for castrate-resistant prostate cancer
Patients with prior radiation therapy completed less than 4 weeks prior enrollment
Patients with prior investigational therapies within 4 weeks before treatment with APC-100
Evidence of active second malignancy